請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34262
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賈景山 | |
dc.contributor.author | Ching-Wen Chen | en |
dc.contributor.author | 陳鏡文 | zh_TW |
dc.date.accessioned | 2021-06-13T06:00:24Z | - |
dc.date.available | 2016-10-05 | |
dc.date.copyright | 2011-10-05 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-26 | |
dc.identifier.citation | Acosta-Rodriguez, E.V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., and Napolitani, G. (2007). Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8, 639-646.
Aggarwal, S., and Gurney, A.L. (2002). IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71, 1-8. Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Fili, L., Ferri, S., Frosali, F., et al. (2007). Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849-1861. Antonysamy, M.A., Fanslow, W.C., Fu, F., Li, W., Qian, S., Troutt, A.B., and Thomson, A.W. (1999). Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J. Immuno.l 162, 577-584. Apostolou, I., Sarukhan, A., Klein, L., and von Boehmer, H. (2002). Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3, 756-763. Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W.H., et al. (2006). Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer. Res. 12, 465-472. Bates, G.J., Fox, S.B., Han, C., Leek, R.D., Garcia, J.F., Harris, A.L., and Banham, A.H. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373-5380. Bensinger, S.J., Bandeira, A., Jordan, M.S., Caton, A.J., and Laufer, T.M. (2001). Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J. Exp. Med. 194, 427-438. Beriou, G., Costantino, C.M., Ashley, C.W., Yang, L., Kuchroo, V.K., Baecher-Allan, C., and Hafler, D.A. (2009). IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113, 4240-4249. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., and Kuchroo, V.K. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238. Blank, C., Gajewski, T.F., and Mackensen, A. (2005). Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54, 307-314. Blatner, N.R., Bonertz, A., Beckhove, P., Cheon, E.C., Krantz, S.B., Strouch, M., Weitz, J., Koch, M., Halverson, A.L., Bentrem, D.J., and Khazaie, K. (2010). In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proceedings of the National Academy of Sciences 107, 6430-6435. Blot, W.J., McLaughlin, J.K., Winn, D.M., Austin, D.F., Greenberg, R.S., Preston-Martin, S., Bernstein, L., Schoenberg, J.B., Stemhagen, A., and Fraumeni, J.F., Jr. (1988). Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 48, 3282-3287. Buckner, J.H. (2010). Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nature Reviews Immunology 10, 849-859. Catlett-Falcone, R., Landowski, T.H., Oshiro, M.M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J.L., Nunez, G., et al. (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115. Chaudhry, A., Rudra, D., Treuting, P., Samstein, R.M., Liang, Y., Kas, A., and Rudensky, A.Y. (2009). CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986-991. Chaudhry, A., Samstein, R.M., Treuting, P., Liang, Y., Pils, M.C., Heinrich, J.M., Jack, R.S., Wunderlich, F.T., Bruning, J.C., Muller, W., and Rudensky, A.Y. (2011). Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34, 566-578. Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., and Wahl, S.M. (2003). Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor FoxP3. J. Exp. Med. 198, 1875-1886. Chung, D.J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D.H., and Young, J.W. (2009). Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114, 555-563. Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867. Curiel, T.J. (2007). Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117, 1167-1174. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949. de Jong, E.C., Vieira, P.L., Kalinski, P., Schuitemaker, J.H., Tanaka, Y., Wierenga, E.A., Yazdanbakhsh, M., and Kapsenberg, M.L. (2002). Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J. Immunol. 168, 1704-1709. Diehl, S., and Rincon, M. (2002). The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 39, 531-536. Dominguez-Villar, M., Baecher-Allan, C.M., and Hafler, D.A. (2011). Identification of T helper type 1-like, FoxP3(+) regulatory T cells in human autoimmune disease. Nat. Med. 17, 673-675. Drake, C.G., Jaffee, E., and Pardoll, D.M. (2006). Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81. Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., and Rudensky, A.Y. (2005). Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329-341. Gershon, R.K., and Kondo, K. (1970). Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18, 723-737. Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P.E., Novault, S., Escudier, B., Vivier, E., et al. (2005). CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202, 1075-1085. Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., and Weaver, C.T. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132. Hashibe, M., Brennan, P., Chuang, S.c., Boccia, S., Castellsague, X., Chen, C., Curado, M.P., Dal Maso, L., Daudt, A.W., Fabianova, E., et al. (2009). Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiology Biomarkers & Prevention 18, 541-550. Hovhannisyan, Z., Treatman, J., Littman, D.R., and Mayer, L. (2011). Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957-965. Inozume, T., Hanada, K., Wang, Q.J., and Yang, J.C. (2009). IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J. Immunother. 32, 109-117. Jarnicki, A.G., Lysaght, J., Todryk, S., and Mills, K.H. (2006). Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177, 896-904. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians 61, 69-90. Karin, M., and Greten, F.R. (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749-759. Kasprzycka, M., Marzec, M., Liu, X., Zhang, Q., and Wasik, M.A. (2006). Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl. Acad. Sci. U. S. A. 103, 9964-9969. Kehlen, A., Thiele, K., Riemann, D., Rainov, N., and Langner, J. (1999). Interleukin-17 stimulates the expression of IkappaB alpha mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J. Neuroimmunol. 101, 1-6. Khong, H.T., and Restifo, N.P. (2002). Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. Immunol. 3, 999-1005. Koch, M.A., Tucker-Heard, G., Perdue, N.R., Killebrew, J.R., Urdahl, K.B., and Campbell, D.J. (2009). The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10, 595-602. Korn, T., Bettelli, E., Oukka, M., and Kuchroo, V.K. (2009). IL-17 and Th17 Cells. Annual Review of Immunology 27, 485-517. Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mule, J., Kerr, W.G., et al. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321. Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T.H., et al. (2009). Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141-1149. Kryczek, I., Wu, K., Zhao, E., Wei, S., Vatan, L., Szeliga, W., Huang, E., Greenson, J., Chang, A., Rolinski, J., et al. (2011). IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer. The Journal of Immunology 186, 4388-4395. La Vecchia, C., Tavani, A., Franceschi, S., Levi, F., Corrao, G., and Negri, E. (1997). Epidemiology and prevention of oral cancer. Oral Oncol. 33, 302-312. Laan, M., Cui, Z.H., Hoshino, H., Lotvall, J., Sjostrand, M., Gruenert, D.C., Skoogh, B.E., and Linden, A. (1999). Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162, 2347-2352. Liu, T.Y., Chen, C.L., and Chi, C.W. (1996). Oxidative damage to DNA induced by areca nut extract. Mutat. Res. 367, 25-31. Manches, O., Munn, D., Fallahi, A., Lifson, J., Chaperot, L., Plumas, J., and Bhardwaj, N. (2008). HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 118, 3431-3439. Mangan, P.R., Harrington, L.E., O'Quinn, D.B., Helms, W.S., Bullard, D.C., Elson, C.O., Hatton, R.D., Wahl, S.M., Schoeb, T.R., and Weaver, C.T. (2006). Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231-234. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica, A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends. Immunol. 23, 549-555. Martin-Orozco, N., Li, Y., Wang, Y., Liu, S., Hwu, P., Liu, Y.J., Dong, C., and Radvanyi, L. (2010). Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 70, 9581-9590. Menetrier-Caux, C., Montmain, G., Dieu, M.C., Bain, C., Favrot, M.C., Caux, C., and Blay, J.Y. (1998). Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92, 4778-4791. Mezrich, J.D., Fechner, J.H., Zhang, X., Johnson, B.P., Burlingham, W.J., and Bradfield, C.A. (2010). An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190-3198. Mullen, A.C. (2001). Role of T-bet in Commitment of TH1 Cells Before IL-12-Dependent Selection. Science 292, 1907-1910. Murray, H.W., and Nathan, C.F. (1999). Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189, 741-746. Nagai, H., Horikawa, T., Hara, I., Fukunaga, A., Oniki, S., Oka, M., Nishigori, C., and Ichihashi, M. (2004). In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol 13, 613-620. Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., and Gabrilovich, D. (2004). Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172, 464-474. Numasaki, M., Lotze, M.T., and Sasaki, H. (2004). Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol. Lett. 93, 39-43. Okumura, K., and Tada, T. (1973). Suppression of hapten-specific antibody response by carrier-specific T cells. Nat. New. Biol. 245, 180-182. Petti, S. (2009). Lifestyle risk factors for oral cancer. Oral Oncol. 45, 340-350. Rhodus, N.L., Ho, V., Miller, C.S., Myers, S., and Ondrey, F. (2005). NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer. Detect. Prev. 29, 42-45. Sakaguchi, S., Miyara, M., Costantino, C.M., and Hafler, D.A. (2010). FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., and Iacopetta, B. (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27, 186-192. Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., and Takabayashi, A. (2003). CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089-1099. Seyerl, M., Kirchberger, S., Majdic, O., Seipelt, J., Jindra, C., Schrauf, C., and Stockl, J. (2010). Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur. J. Immunol. 40, 321-329. Sfanos, K.S., Bruno, T.C., Maris, C.H., Xu, L., Thoburn, C.J., DeMarzo, A.M., Meeker, A.K., Isaacs, W.B., and Drake, C.G. (2008). Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer. Res. 14, 3254-3261. Shevach, E.M. (2002). CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400. Smith, E.M., Hoffman, H.T., Summersgill, K.S., Kirchner, H.L., Turek, L.P., and Haugen, T.H. (1998). Human papillomavirus and risk of oral cancer. Laryngoscope 108, 1098-1103. Sugimoto, N., Oida, T., Hirota, K., Nakamura, K., Nomura, T., Uchiyama, T., and Sakaguchi, S. (2006). FoxP3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int. Immunol. 18, 1197-1209. Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G., and Glimcher, L.H. (2000). A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655-669. Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid, Y., and Shevach, E.M. (2010). Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced FoxP3+ T regulatory cells. J. Immunol. 184, 3433-3441. Tran, D.Q., Ramsey, H., and Shevach, E.M. (2007). Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110, 2983-2990. Tsushima, F., Tanaka, K., Otsuki, N., Youngnak, P., Iwai, H., Omura, K., and Azuma, M. (2006). Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 42, 268-274. van den Broeke, L.T., Daschbach, E., Thomas, E.K., Andringa, G., and Berzofsky, J.A. (2003). Dendritic cell-induced activation of adaptive and innate antitumor immunity. J. Immunol. 171, 5842-5852. von Euw, E., Chodon, T., Attar, N., Jalil, J., Koya, R.C., Comin-Anduix, B., and Ribas, A. (2009). CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7, 35. Voo, K.S., Wang, Y.H., Santori, F.R., Boggiano, C., Arima, K., Bover, L., Hanabuchi, S., Khalili, J., Marinova, E., Zheng, B., et al. (2009). Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc. Natl. Acad. Sci. U. S. A 106, 4793-4798. Walker, M.R., Carson, B.D., Nepom, G.T., Ziegler, S.F., and Buckner, J.H. (2005). De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc. Natl. Acad. Sci. U. S. A. 102, 4103-4108. Wang, J., Huizinga, T.W., and Toes, R.E. (2009). De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid. J. Immunol. 183, 4119-4126. Wei, J., Barr, J., Kong, L.Y., Wang, Y., Wu, A., Sharma, A.K., Gumin, J., Henry, V., Colman, H., Sawaya, R., et al. (2010). Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer. Res. 16, 461-473. Yang, S., Wang, B., Guan, C., Wu, B., Cai, C., Wang, M., Zhang, B., Liu, T., and Yang, P. (2010). FoxP3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. Journal of Leukocyte Biology 89, 85-91. Zhang, J.P., Yan, J., Xu, J., Pang, X.H., Chen, M.S., Li, L., Wu, C., Li, S.P., and Zheng, L. (2009). Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50, 980-989. Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J.M., Chu, T.T., Corcoran, L., Treuting, P., Klein, U., and Rudensky, A.Y. (2009). Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458, 351-356. Zhu, J., Yamane, H., and Paul, W.E. (2010). Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28, 445-489. Zienolddiny, S., Aguelon, A.M., Mironov, N., Mathew, B., Thomas, G., Sankaranarayanan, R., and Yamasaki, H. (2004). Genomic instability in oral squamous cell carcinoma: relationship to betel-quid chewing. Oral Oncol. 40, 298-303. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34262 | - |
dc.description.abstract | 口腔癌近年來在台灣癌症排名中,從過去的十名之外大幅提昇到第六名,在男性癌症致死率的排名更是高居第四,對國民健康造成重大的威脅。口腔癌中以口腔鱗狀細胞癌最為常見,佔口腔癌的90%以上,在口腔癌研究中本實驗室先前研究發現調節性T細胞與Th17細胞在口腔麟狀上皮細胞癌病患的腫瘤浸潤細胞中都有高量比例之分佈,並且也發現一群特殊的細胞群同時表現IL-17+Foxp3+,然而此群細胞在口腔癌微環境扮演的角色仍不清楚,且在口腔癌症微環境中,口腔癌症細胞是如何逃避免疫細胞的辨認和攻擊,仍需進一步的探討。本研究將腫瘤浸潤細胞從口腔癌組織中分離,將其染色後利用流式細胞儀分析,發現IL-17+Foxp3+與IL-17-Foxp3+ 調節性T細胞均表現高量的CTLA-4,但都不會分泌IFN,IL-2和IL-22。為了進一步研究IL-17-Foxp3+調節性T細胞在癌症環境中的功能,本研究利用與Th17相關的化學趨化因子受體CCR6作為標記,分離出CCR6+CD25+和CCR6-CD25+兩群調節性T細胞,確認CCR6+CD25+放出較高量的IL-17,且在體外實驗中具有較強的免疫抑制能力。而在CD4+ T細胞與口腔麟狀上皮細胞癌細胞株SAS的共同培養系統中,進一步的確認本實驗室先前的發現SAS細胞與CD4+ T細胞共同培養誘發Foxp3+調節性T細胞,主要是來自記憶性T細胞(CD45RO+),並具有體外的免疫抑制能力的。共同培養系統中也發現癌細胞株能夠直接抑制CD4+ T細胞的增生及釋放IFN和IL-2。利用1-methyl-tryptophan (1-MT)更進一步發現SAS細胞可能是透過indoleamine 2,3-dioxygenase (IDO) 去抑制CD4+ T細胞而與B7H1無關。總結本研究認為IL-17+Foxp3+調節性T細胞在口腔癌癌環境中扮演了較強免疫抑制的角色;而在與SAS細胞共同培養實驗中,則發現口腔癌細胞可以直接抑制免疫細胞的活性與增生。 | zh_TW |
dc.description.abstract | Oral cancer is one of the major health issues in Taiwan. Around 90% of oral cancer is oral squamous cells carcinoma (OSCC). Our laboratory previously demonstrated that in OSCC, Th17 cells and Treg cells are increased in tumor infiltrating lymphocytes (TILs). Most interestingly, a specific subset of T cells, IL-17+Foxp3+, is also increased in TILs. However, the function and phenotype of IL-17+Foxp3+ Treg cells and the immunosuppressive mechanisms of oral cancer cell are not clear. Therefore the main purposes of this study are to delineate the functional characteristics of IL-17+ FoxP3+ CD4+ T cells and the interaction between oral cancer SAS cells and CD4+ T cells in vitro. TILs were stained by intracellular staining and analyzed by flow cytometry. The IL-17+ Treg cells produced a significantly higher level of IL-10 than IL-17- Treg cells, but the production of IL-2, IFN-γ, CTLA-4 or IL-22 were similar. The IL-17+ or IL-17- Treg cells were purified based on the expression of CCR6 by cell sorting. The expression level of il17 or rorc was significantly higher in CD4+CD25+CCR6+ than CCR6- Treg cells. Moreover, IL-17+ Treg cells displayed higher suppressive activity than IL-17- Treg cells in vitro. When co-cultured with SAS cells, purified memory (CD45RO+), but not naive (CD45RO-), CD4+ T cells exhibited enhanced expression of FoxP3 and suppressive activity with down-regulation of IFN-γ and IL-2. The SAS-mediated inhibition of T cells is reversed by the inhibitor of indoleamine 2,3-dioxygenase (IDO) and is independent of B7H1. Taken together, these results suggested that IL-17+ Treg cells may exhibit a higher suppressive activity in the oral cancer microenvironment, and the cancer cell alone is sufficient to inhibit directly the T cell activation and proliferation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:00:24Z (GMT). No. of bitstreams: 1 ntu-100-R98449010-1.pdf: 2857721 bytes, checksum: 1783071a8f8863b94511cf5f978af202 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄
口試委員會審定書..............................................i 致謝......................................................ii 中文摘要..................................................iii Abstruct..................................................iv Chapter 1.Introduction.....................................1 1.1. Oral Cancers.......................................1 1.2. CD4 T helper cells in tumor microenvironment.......3 1.2.1. T helper 1 cells (Th1).............................3 1.2.2. T helper 2 cells (Th2).............................4 1.2.3. T helper 17 cells (Th17)...........................4 1.2.4. Regulatory T cells (Treg)..........................7 1.3. Developmental plasticity of Th17 and Treg cells....9 1.4. Induction of iTreg in human.......................11 1.5. Immunosuppressive mechanism employed by tumor cells ..........................................................11 1.6. The role of pSTAT3 in tumor microenvironment......13 Chapter 2. Purposes and Aims.........................15 Chapter 3. Materials and methods.....................16 3.1. Isolation of tumor-infiltrating lymphocytes(TILs) ..........................................................16 3.2. Isolation of peripheral blood mononuclear cells and CD4 T cells...............................................16 3.3. Human oral cancer cell line and T cell co-culture.17 3.4. Surface and Intracellular staining................18 3.5. ELISA.............................................18 3.6. Suppression Assay.................................18 3.7. RNA extraction....................................19 3.8. Reverse Transcription.............................20 3.9. Polymerase Chain Reaction (PCR) and Real-time PCR.21 3.10. Statistical analysis..............................22 Chapter 4. Results...................................23 4.1. The frequency of IL-17+, FoxP3+ and IL-17+FoxP3+ T cells were significantly higher in TILs than in PBMCs.....23 4.2. The phenotype of IL-17+FoxP3+ T cells.............24 4.3. CCR6 is a marker of IL-17+FoxP3+ T cells..........25 4.4. IL-17+FoxP3+ T cells possess the suppressive function..................................................26 4.5. IL-17+FoxP3+ T cells correlation to IL10+ T cells.27 4.6. Oral cancer SAS cells mediate immunosuppression on human T cells.............................................27 4.7. SAS inhibit CD4+ proliferation and IFN-γ, IL-2 production through IDO....................................29 4.8. Induction of FoxP3+ cells in the presence of SAS cells.....................................................30 4.9. Induction of FoxP3+ T cells is independent on B7H1 or IDO....................................................31 4.10. Induced FoxP3+ T cells contain the suppressive function..................................................32 Chapter 5. Discussion................................33 Chapter 6. References................................37 Chapter 7. Figures...................................46 | |
dc.language.iso | en | |
dc.title | 從口腔癌分離或共同培養誘發之產生介白素-17之調節性T細胞之特性分析 | zh_TW |
dc.title | Characterization of IL-17-producing and -non-producing Treg cells isolated from human oral squamous cell carcinoma or derived from in vitro co-culture system | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 賴明宗,王莉芳 | |
dc.subject.keyword | 口腔癌,調節性T細胞,介白素-17,免疫抑制, | zh_TW |
dc.subject.keyword | OSCC,Treg,IL-17,immunosuppressive, | en |
dc.relation.page | 54 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 2.79 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。